Sign In
Buy ABBV
$250.88
-6.74 (-2.61%)
At Close: Jul 31, 2026
Merck, AbbVie probed by US lawmakers over China clinical trials: report
12:35pm, Tuesday, 30'th Jun 2026
A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
12:31pm, Tuesday, 30'th Jun 2026
Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 30'th Jun 2026
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Merck, AbbVie probed by US lawmakers over China clinical trials: report
08:19am, Tuesday, 30'th Jun 2026
A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck...
Topline results from Phase 3 EPCORE ® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression
ABBV Gets CHMP Nod for Rinvoq in Two Different Autoimmune Diseases
12:25pm, Monday, 29'th Jun 2026
AbbVie wins positive CHMP opinions for Rinvoq in severe alopecia areata and non-segmental vitiligo, with EU decisions expected in the coming months.
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
12:11pm, Monday, 29'th Jun 2026
LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.
3 No-Brainer Dividend Stocks to Buy Right Now
11:43am, Monday, 29'th Jun 2026
AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?
11:21am, Monday, 29'th Jun 2026
AbbVie has outperformed the market this year, but its valuation remains modest. The company recently announced the acquisition of Apogee Therapeutics, further diversifying its operations.
AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?
11:21am, Monday, 29'th Jun 2026
AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score ≤ 20 and key secondar
If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs for those living with the chronic, unpredictabl
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
04:50pm, Friday, 26'th Jun 2026
SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a new 55 mg pre-filled syri
Lilly, J&J and AbbVie Hit New Highs
12:49pm, Friday, 26'th Jun 2026
Healthcare stocks outperformed the broader market on Friday, with Eli Lilly (LLY), Johnson and Johnson (JNJ) and AbbVie (ABBV) among the major names hitting fresh
